cGAS-STING Signaling in Parkinson's Disease

cGAS-STING Signaling in Parkinson's Disease

The cGAS-STING signaling pathway has emerged as a critical driver of neuroinflammation and dopaminergic neurodegeneration in Parkinson's disease (PD). Originally characterized as a cytosolic DNA sensing pathway fundamental to antiviral immunity, cGAS-STING activation in the brain contributes to chronic neuroinflammation, mitochondrial dysfunction, and astrocyte senescence—all key hallmarks of PD pathogenesis. Understanding this pathway provides novel therapeutic targets for disease-modifying interventions.

The cGAS-STING Pathway: Molecular Mechanism

The cGAS-STING pathway represents a key innate immune sensing system that detects cytosolic DNA and initiates a type I interferon (IFN) response. The canonical pathway proceeds through sequential activation of several key proteins: [@neuroinflammation2024]

cGAS (cyclic GMP-AMP synthase): This cytosolic DNA sensor binds double-stranded DNA (dsDNA) regardless of sequence, undergoing a conformational change that enables its enzymatic activity. cGAS catalyzes the synthesis of the second messenger cGAMP (cyclic guanosine monophosphate-adenosine monophosphate) from ATP and GTP.

STING (Stimulator of Interferon Genes): STING is an endoplasmic reticulum (ER)-anchored transmembrane protein that translocates to the Golgi apparatus upon binding cGAMP. In the Golgi, STING recruits TBK1 (TANK-binding kinase 1), which phosphorylates IRF3 (Interferon Regulatory Factor 3).

...

cGAS-STING Signaling in Parkinson's Disease

The cGAS-STING signaling pathway has emerged as a critical driver of neuroinflammation and dopaminergic neurodegeneration in Parkinson's disease (PD). Originally characterized as a cytosolic DNA sensing pathway fundamental to antiviral immunity, cGAS-STING activation in the brain contributes to chronic neuroinflammation, mitochondrial dysfunction, and astrocyte senescence—all key hallmarks of PD pathogenesis. Understanding this pathway provides novel therapeutic targets for disease-modifying interventions.

The cGAS-STING Pathway: Molecular Mechanism

The cGAS-STING pathway represents a key innate immune sensing system that detects cytosolic DNA and initiates a type I interferon (IFN) response. The canonical pathway proceeds through sequential activation of several key proteins: [@neuroinflammation2024]

cGAS (cyclic GMP-AMP synthase): This cytosolic DNA sensor binds double-stranded DNA (dsDNA) regardless of sequence, undergoing a conformational change that enables its enzymatic activity. cGAS catalyzes the synthesis of the second messenger cGAMP (cyclic guanosine monophosphate-adenosine monophosphate) from ATP and GTP.

STING (Stimulator of Interferon Genes): STING is an endoplasmic reticulum (ER)-anchored transmembrane protein that translocates to the Golgi apparatus upon binding cGAMP. In the Golgi, STING recruits TBK1 (TANK-binding kinase 1), which phosphorylates IRF3 (Interferon Regulatory Factor 3).

IRF3 Activation: Phosphorylated IRF3 dimerizes and translocates to the nucleus, where it induces transcription of type I interferons (IFN-α, IFN-β) and pro-inflammatory cytokines.

IRF7 as Amplifier: In neurons and glial cells, IRF7 is markedly upregulated downstream of cGAS-STING and serves as an additional transcription factor amplifying the inflammatory response. IRF7 activation in PD models mediates neuroinflammation through enhanced cytokine production.

cGAS-STING in PD Pathogenesis

Astrocyte Senescence

A critical insight from recent research is that cGAS-STING activation in astrocytes drives cellular senescence, which contributes substantially to dopaminergic neuron loss. In PD models and aged brains, the pathway is markedly upregulated in senescent astrocytes. [@lcn2023]

The molecular cascade involves: [@transcriptional2024]

• STING-YY1 Interaction: STING binds to YY1 (Yin Yang 1), a transcription factor, preventing its nuclear translocation
• LCN2 Upregulation: YY1 sequestration leads to increased transcription of LCN2 (Lipocalin-2) in astrocytes
• Senescence-Associated Secretory Phenotype (SASP): Senescent astrocytes release pro-inflammatory factors including IL-6, IL-1α, IL-1β, MMP3, and MMP9
• Neurotoxicity: These SASP factors promote neuroinflammation and dopaminergic neuron death

Genetic deletion of astrocytic cGAS significantly prevents astrocyte senescence and subsequent neurodegeneration in mouse models, demonstrating the causal role of this pathway. [@alphasynuclein2024]

The Senescence-Associated Secretory Phenotype (SASP) in PD

The SASP is a hallmark of cellular senescence and consists of numerous pro-inflammatory factors that profoundly impact the brain microenvironment: [@microglial2024]

Cytokines [@endolysosomal2024]

• IL-6: Potent pro-inflammatory cytokine that promotes microglial activation and neuronal dysfunction
• IL-1α/IL-1β: Major drivers of neuroinflammation, activating NF-κB signaling
• TNF-α: Tumor necrosis factor alpha contributes to excitotoxicity and neuronal death

Matrix Metalloproteinases (MMPs) [@autophagylysosome2023]

• MMP3: Degrades extracellular matrix proteins and activates pro-IL-1β
• MMP9: Involved in blood-brain barrier disruption and leukocyte infiltration

Chemokines [@dna2024a]

• CXCL1, CXCL8: Recruit neutrophils and other immune cells to the brain
• CCL2/MCP-1: Monocyte chemoattractant promoting microglial infiltration

Growth Factors and Other Mediators [@therapeutic2024]

• VEGF: Alters blood-brain barrier permeability
• PAI-1: Serpin inhibitor affecting fibrinolysis
• GRO-α: Pro-inflammatory chemokine

The chronic release of SASP factors from senescent astrocytes creates a persistent neuroinflammatory environment that accelerates dopaminergic neurodegeneration. Importantly, SASP factors can also induce senescence in neighboring cells through paracrine effects, spreading the senescent phenotype throughout the brain. [@mptp2023]

Mitochondrial Dysfunction Connection

The link between mitochondrial dysfunction and cGAS-STING activation in PD is bidirectional: [@ohda2024]

• Mitochondrial DNA Release: Mitochondrial dysfunction leads to mitochondrial DNA (mtDNA) release into the cytosol, where it can activate cGAS
• cGAS-Mfn2 Signaling: Studies show metformin can restore mitochondrial function through Mfn2-cGAS signaling, delaying astrocyte senescence
• DNA Damage-cGAS Loop: DNA damage fuels cGAS activation, creating a vicious cycle linking genome instability to neuroinflammation

Mitochondrial cGAS: A Novel Pathway

The mitochondria represent a critical source of cytosolic DNA that activates cGAS in PD: [@rotenone2024]

Mechanisms of Mitochondrial DNA Release [@lrrk2024]

Mitochondrial Permeability Transition Pore (mPTP): Opening of the mPTP allows mtDNA release

Mitochondrial Outer Membrane Permabilization (MOMP): Pro-apoptotic proteins like Bax/Bak can create pores

VDAC Opening: Voltage-dependent anion channel (VDAC) in the outer membrane can permit mtDNA passage

Bax/Bak Pores: Pro-apoptotic Bcl-2 family proteins form pores releasing mtDNA

Mitochondrial-Nuclear DNA Sensing [@pink2024]
The cell must distinguish mtDNA from nuclear DNA to prevent inappropriate immune activation: [@postmortem2024]

• mtDNA lacks histone protection and is packaged differently
• The nuclear envelope normally separates nuclear DNA from cytoplasmic sensors
• mtDNA is normally contained within the mitochondrial network

Therapeutic Implications of Mitochondrial cGAS [@cgassting2023a]
Targeting mitochondrial cGAS activation represents a promising approach: [@sting2023]

• Protecting mitochondrial integrity prevents cGAS activation
• VDAC blockers may prevent mtDNA release
• Mitochondrial-targeted antioxidants reduce oxidative DNA damage
• Mfn2 agonists (like metformin) restore mitochondrial function

DNA Damage Response

Recent evidence demonstrates a direct DNA damage-cGAS-STING loop in PD: [@tbk2024]

• DNA damage in dopaminergic neurons activates cGAS
• cGAS-STING signaling drives neuroinflammation
• Neuroinflammation further exacerbates DNA damage
• This creates a self-perpetuating cycle promoting dopaminergic neurodegeneration

Autophagy Dysregulation

STING activation induces non-canonical autophagy that alters endolysosomal homeostasis: [@irfmediated2024]

• STING trafficking to the Golgi triggers autophagy initiation
• Autophagy dysregulation impairs protein clearance
• Accumulation of damaged proteins and organelles ensues
• Contributes to α-synuclein pathology

The cGAS-STING pathway represents a critical innate immune signaling cascade that links cytosolic DNA sensing to neuroinflammation in Parkinson's disease (PD). This pathway has emerged as a key contributor to chronic neuroinflammation, mitochondrial dysfunction, and dopaminergic neuron loss characteristic of PD pathophysiology. [@cgamp2024]

Overview

Cyclic GMP-AMP synthase (cGAS) is a cytosolic DNA sensor that detects aberrant DNA in cells. Upon binding to double-stranded DNA, cGAS catalyzes the production of cyclic guanine-adenine monophosphate (cGAMP), a second messenger that activates the endoplasmic reticulum-associated protein STING (Stimulator of Interferon Genes). This activation triggers a type I interferon response and pro-inflammatory cytokine production. [@gdf2024a]

In Parkinson's disease, the cGAS-STING pathway becomes chronically activated through multiple mechanisms: [@metformin2024a]

• Mitochondrial DNA (mtDNA) release into the cytosol due to mitochondrial dysfunction
• Accumulation of nuclear DNA damage
• Glial cell activation in response to alpha-synuclein aggregates
• Bacterial/viral DNA from environmental exposures

Molecular Mechanism

cGAS Activation

cGAS consists of an N-terminal unstructured region and a C-terminal catalytic domain. In the inactive state, cGAS exists in an autoinhibited dimeric form. DNA binding induces conformational changes that allow cGAS to form ladder-like dimers on DNA, enabling catalytic activity. [@alphasynuclein2024a]

The enzymatic reaction produces cGAMP from ATP and GTP: [@microglial2024a]

• cGAS + DNA → cGAS-DNA complex
• cGAS-DNA complex catalyzes: 2 ATP + 2 GTP → cGAMP + 2 PPi

cGAMP then binds to STING, inducing its conformational change and translocation to the Golgi apparatus. [@white2024]

STING Activation and Signaling

STING is a transmembrane protein localized to the endoplasmic reticulum. Upon cGAMP binding: [@multiple2024]

STING undergoes conformational change

STING translocates to the Golgi apparatus

STING recruits and activates TBK1 (TANK-binding kinase 1)

TBK1 phosphorylates STING and IRF3 (Interferon Regulatory Factor 3)

Phosphorylated IRF3 translocates to the nucleus

IRF3 induces transcription of type I interferons (IFN-α, IFN-β) and pro-inflammatory genes

Role in Parkinson's Disease Pathology

Mitochondrial Dysfunction

Mitochondrial dysfunction is a hallmark of PD. Damaged mitochondria release mtDNA into the cytosol, where it acts as a potent cGAS agonist. Studies have shown that: [@sting2024]

• Complex I deficiency in dopaminergic neurons leads to increased mtDNA release
• PINK1 and Parkin mutations impair mitophagy, causing accumulation of dysfunctional mitochondria
• Cytosolic mtDNA activates cGAS, creating a feed-forward loop between mitochondrial dysfunction and neuroinflammation

Alpha-Synuclein Aggregation

Alpha-synuclein (αSyn) aggregates can induce DNA damage in neurons and glia. This aggregate-associated DNA damage activates cGAS-STING signaling through: [@cgassting2024a]

• Nuclear envelope disruption
• Micronucleus formation
• Retrotransposon activation

The resulting interferon response exacerbates neuroinflammation and promotes progressive dopaminergic neuron loss. [@innate2024]

Glial Cell Activation

Microglia and astrocytes show robust cGAS-STING activation in PD brains:

• Elevated cGAS and STING expression in substantia nigra of PD patients
• Increased cGAMP production in activated microglia
• STING-dependent production of TNF-α, IL-6, and other pro-inflammatory cytokines

Neuroinflammation

Chronic cGAS-STING activation leads to:

• Sustained type I interferon response
• Upregulation of interferon-stimulated genes (ISGs)
• Recruitment of immune cells to the substantia nigra
• Enhanced antigen presentation and adaptive immune activation

Therapeutic Implications

STING Inhibitors

Several STING inhibitors are being investigated for PD:

• Small-molecule inhibitors targeting STING binding pocket
• Blocking STING trafficking to the Golgi
• Preventing TBK1 recruitment

Downstream Target Modulation

• LCN2 Inhibition: Blocking LCN2 may prevent astrocyte senescence
• IRF7 Targeting: Reducing IRF7 activation could dampen neuroinflammation
• YY1 Modulation: Restoring YY1 nuclear translocation

Drug Repurposing

• Metformin: Mfn2-cGAS signaling mediates neuroprotective effects
• GDF15: Growth Differentiation Factor 15 attenuates PD progression by suppressing cGAS-STING
• 3-N-butylphthalide (NBP): Reduces neuroinflammation in rotenone-induced PD models via cGAS-STING inhibition

Cross-Linking to Related Mechanisms

The cGAS-STING pathway intersects with numerous other PD mechanisms:

• [Alpha-synuclein Pathology](/mechanisms/alpha-synuclein-pathology): cGAS-STING activation can be induced by α-synuclein aggregates
• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/pd-mitochondrial-dysfunction): Bidirectional relationship with cGAS-STING
• [Neuroinflammation and Microglia Pathway in Parkinson's Disease](/mechanisms/pd-neuroinflammation-microglia-pathway): cGAS-STING drives microglial activation
• [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-neurodegeneration): Creates feed-forward loop
• [Autophagy Dysfunction in Parkinson's Disease](/mechanisms/pd-autophagy-lysosome-pathway): STING-induced autophagy alterations

Animal Models of cGAS-STING in PD

MPTP and 6-OHDA Models

Several PD animal models have demonstrated cGAS-STING pathway activation:

• MPTP Model: MPTP administration induces mitochondrial dysfunction and DNA damage, leading to cGAS-STING activation in the substantia nigra
• 6-OHDA Model: 6-hydroxydopamine lesions trigger cytosolic DNA accumulation and subsequent cGAS-STING signaling
• Rotenone Model: Rotenone-induced mitochondrial complex I inhibition activates cGAS-STING through multiple mechanisms

MPTP Model: Detailed Mechanisms

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted to MPP+ by MAO-B in astrocytes, which then selectively accumulates in dopaminergic neurons through the dopamine transporter:

cGAS-STING Activation in MPTP

MPP+ inhibits complex I of the mitochondrial electron transport chain

This leads to mitochondrial membrane potential loss and ATP depletion

Mitochondrial dysfunction triggers mtDNA release into cytosol

Cytosolic mtDNA activates cGAS

cGAMP production activates STING

TBK1-IRF3 signaling induces type I IFN response

Pro-inflammatory cytokines are released

Dopaminergic neurons undergo apoptosis

The timeline of events:

• 0-6 hours: Mitochondrial dysfunction onset
• 6-24 hours: cGAS-STING activation begins
• 24-72 hours: Peak neuroinflammation and cytokine release
• 1-7 days: Dopaminergic neuron death

6-OHDA Model: Oxidative Stress and cGAS

6-hydroxydopamine (6-OHDA) is a hydroxylated analog of dopamine that undergoes auto-oxidation:

Mechanism of Action

6-OHDA enters neurons via catecholamine transporters

It undergoes auto-oxidation generating hydrogen peroxide and superoxide radicals

Massive oxidative stress damages mitochondria

DNA damage occurs from reactive oxygen species

Nuclear and mitochondrial DNA fragments accumulate in cytosol

cGAS is activated by cytosolic DNA

STING-dependent inflammation follows

This model demonstrates the direct link between oxidative stress, DNA damage, and cGAS-STING activation.

Rotenone Model: Chronic Exposure

Rotenone is a natural compound that inhibits mitochondrial complex I:

Chronic Rotenone Administration Effects

• Sustained complex I inhibition
• Progressive mitochondrial dysfunction
• Chronic cGAS-STING activation
• Continuous neuroinflammation
• α-synuclein aggregation
• Lewy body-like inclusions

The rotenone model is particularly relevant as it recapitulates several key features of PD, including:

• Progressive dopaminergic degeneration
• α-synuclein pathology
• Mitochondrial dysfunction
• Neuroinflammation (via cGAS-STING)

Genetic Models

• α-Synuclein Transgenic Models: α-synuclein overexpression leads to mitochondrial damage and cGAS-STING activation
• Parkinsonian Mouse Models: LRRK2 G2019S mutation enhances cGAS-STING-mediated neuroinflammation
• PINK1 and DJ-1 Models: Loss-of-function models show increased cGAS-STING activation due to mitochondrial dysfunction

α-Synuclein Models and cGAS-STING

Transgenic mice expressing human α-synuclein under various promoters show:

• Progressive α-synuclein aggregation
• Mitochondrial dysfunction in dopaminergic neurons
• Elevated cGAS-STING activation
• Neuroinflammation correlating with pathology

The connection between α-synuclein and cGAS-STING:

α-synuclein aggregates can damage mitochondria

Mitochondrial damage releases mtDNA

mtDNA activates cGAS-STING

Creates feed-forward loop: α-synuclein → mitochondrial damage → cGAS-STING → inflammation → more α-synuclein aggregation

LRRK2 G2019S and Innate Immunity

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are the most common genetic cause of familial PD:

• G2019S mutation increases kinase activity
• Enhanced microglial activation
• Increased cGAS-STING signaling
• Elevated type I IFN response

LRRK2 is expressed in microglia and its mutant form:

• Amplifies TLR signaling
• Enhances NF-κB activation
• Potentiates cGAS-STING response
• May increase susceptibility to neuroinflammation

PINK1 and DJ-1 Models

Recessive genes PINK1 and DJ-1 cause early-onset PD:

• Loss of PINK1 impairs mitophagy
• Loss of DJ-1 affects oxidative stress response
• Both lead to mitochondrial dysfunction
• Both result in cGAS-STING activation

Evidence from Human Tissue

Post-mortem studies of PD brains reveal:

• Increased cGAS and STING expression in the substantia nigra
• Elevated pTBK1 and pIRF3 in dopaminergic neurons
• STING-positive astrocytes in areas of neurodegeneration
• Correlation between cGAS-STING activation and disease severity

Immunohistochemical Findings

Studies examining post-mortem PD brain tissue show:

• cGAS: Strong immunoreactivity in substantia nigra neurons and glia
• STING: Increased expression in dopaminergic neurons
• pTBK1: Elevated phosphorylation in affected brain regions
• pIRF3: Nuclear translocation in neurons indicating activation
• LCN2: Increased in astrocytes near degenerating neurons

Gene Expression Studies

Transcriptomic analysis of PD brains reveals:

• Upregulation of type I IFN-stimulated genes (ISGs)
• Increased expression of pro-inflammatory cytokines
• Elevated senescence markers (p16, p21)
• Enhanced DNA damage response genes

Evidence from Human Studies

CSF Biomarker Studies

Cerebrospinal fluid analysis in PD patients shows:

• Elevated cGAMP levels compared to controls
• Increased IFN-β in early PD
• Correlation between cGAMP and disease progression
• Potential for cGAMP as disease progression biomarker

Genetic Studies

Genetic variants in cGAS-STING pathway genes may influence PD risk:

• STING polymorphisms associated with PD susceptibility
• cGAS variants potentially modifying disease onset
• Ongoing GWAS studies examining pathway genes

Molecular Details of Pathway Activation

Triggers of cGAS Activation in PD

Multiple sources of cytosolic DNA can activate cGAS in the PD brain:

Mitochondrial DNA (mtDNA): mtDNA release due to mitochondrial permeability transition or mitochondrial outer membrane permeabilization

Nuclear DNA Fragments: DNA damage from oxidative stress leads to nuclear DNA fragment release

Retroelements: Activation of endogenous retroviruses and LINE-1 elements

Exogenous DNA: Potential viral or bacterial DNA from chronic infections

Neutrophil Extracellular Traps (NETs): Neutrophil-derived DNA in brain parenchyma

Retroelement Activation in PD

Endogenous retroelements represent an underappreciated source of cytosolic DNA:

• LINE-1 (L1) elements: Autonomous retrotransposons active in neurons
• Alu elements: Non-autonomous SINE elements
• Human endogenous retroviruses (HERVs): Ancient viral integrations

In PD, several factors may promote retroelement activation:

• DNA hypomethylation: Age-associated changes in epigenetic regulation
• Oxidative stress: Can promote retrotransposition
• DNA repair impairment: Failure to suppress active elements

Activated retroelements can:

• Generate cytosolic DNA through reverse transcription
• Create copy-prone DNA intermediates
• Trigger cGAS-STING via nucleic acid sensing
• Contribute to chronic inflammation

STING Post-Translational Modifications

STING activity is regulated by multiple post-translational modifications:

• Palmitoylation: Required for STING Golgi translocation and activation. Palmitoylation at Cys88 and Cys91 enables membrane association and signaling
• Phosphorylation: TBK1-mediated phosphorylation at Ser365 is critical for IRF3 activation. This phosphorylation creates a docking site for IRF3
• Ubiquitination: K27-linked ubiquitination promotes STING activation, while K48-linked ubiquitination targets for degradation. K63-linked ubiquitination is required for signaling
• SUMOylation: SUMOylation negatively regulates STING signaling through inhibitory interactions
• Acetylation: Histone acetyltransferases can influence STING expression

Negative Regulators

Several endogenous mechanisms constrain cGAS-STING signaling:

• cGAS Serine Phosphorylation: Casein kinase 2 (CK2) phosphorylates cGAS to limit its activity
• IRF3 Negative Regulators: USP15 and USP29 deubiquitinate STING to limit signaling
• Autophagy-mediated Degradation: Selective autophagy targets activated STING for lysosomal degradation
• p53-mediated Suppression: p53 can repress cGAS transcription
• A20/TNFAIP3: Deubiquitinase that negatively regulates STING

Cyclic GMP-AMP (cGAMP) Dynamics

cGAMP is the second messenger that links cGAS to STING:

cGAMP Structure and Function

• 2',3'-cGAMP contains mixed phosphodiester bonds
• Binds STING with high affinity (Kd ~ 1-5 nM)
• Can diffuse between cells through gap junctions
• Can be transmitted through extracellular vesicles

cGAMP in PD

• Elevated in brain tissue and CSF of PD patients
• Can serve as biomarker for pathway activation
• May spread activation between cells
• Production increases with age

Cell-Type Specific Effects

Neurons

In dopaminergic neurons, cGAS-STING activation leads to:

• Type I interferon response that disrupts neuronal function
• Pro-apoptotic signaling through IRF3
• Disruption of calcium homeostasis
• Impaired mitochondrial function
• Synaptic dysfunction
• Reduced dopamine synthesis

Astrocytes

Astrocytic cGAS-STING activation is particularly important:

• Drives astrocyte senescence (SASP release)
• Impairs astrocytic support of neuronal health
• Promotes neurotoxic astrocyte phenotype
• Disrupts glutamate uptake
• Alters blood-brain barrier maintenance
• Reduces astrocytic neurotrophic support

Microglia

Microglial cGAS-STING signaling contributes to:

• Chronic neuroinflammation
• Phagocytic dysfunction
• Pro-inflammatory cytokine release
• Enhanced surveillance of α-synuclein aggregates
• Synaptic pruning abnormalities
• Border-associated macrophage activation

Oligodendrocytes

Less studied but emerging evidence suggests:

• cGAS-STING activation may contribute to white matter abnormalities
• Possible role in MSA (Multiple System Atrophy) pathogenesis
• Myelin maintenance dysfunction
• Oligodendrocyte precursor cell dysregulation

Biomarkers and Diagnostic Potential

Circulating Biomarkers

Potential biomarkers for cGAS-STING activation in PD:

• cGAMP in CSF: Elevated cGAMP in cerebrospinal fluid
• Serum STING: Soluble STING levels correlate with disease progression
• Type I IFN Signature: Peripheral blood mononuclear cell (PBMC) interferon signature

Imaging Biomarkers

• PET Tracers: Development of STING-targeted PET ligands
• MRI: Changes in neuroinflammation markers

Therapeutic Strategies in Development

Small-Molecule STING Inhibitors

| Compound | Stage | Mechanism |
|----------|-------|----------|
| H-151 | Preclinical | Covalent STING inhibitor |
| C-176 | Preclinical | STING palmitoylation inhibitor |
| Asterisc | Preclinical | STING trafficking blocker |
| Nitro-fatty acids | Preclinical | Adduct formation with STING |

Repurposing Candidates

| Drug | Original Use | cGAS-STING Mechanism |
|------|--------------|---------------------|
| Metformin | Diabetes | Mfn2-cGAS axis modulation |
| Aspirin | Anti-inflammatory | NF-κB inhibition downstream of STING |
| Minocycline | Antibiotic | Microglial activation suppression |
| GDF15 | Investigational | Direct STING suppression |

Gene Therapy Approaches

• CRISPR-based STING knockout: Selective neuronal or glial targeting
• AAV-delivered decoy STING: Soluble STING to sequester cGAMP
• cGAS targeting sgRNAs: Reduce cGAS expression

Future Directions

Key questions remain:

What is the relative contribution of neuronal vs. glial cGAS-STING in PD?

Can STING inhibition prevent α-synuclein pathology progression?

What triggers initial cGAS-STING activation in PD?

Is there a therapeutic window for intervention?

Biomarker development for patient selection

See Also

• [Alpha-synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/pd-mitochondrial-dysfunction)
• [Neuroinflammation and Microglia Pathway in Parkinson's Disease](/mechanisms/pd-neuroinflammation-microglia-pathway)
• [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-neurodegeneration)
• [Autophagy Dysfunction in Parkinson's Disease](/mechanisms/pd-autophagy-lysosome-pathway)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Research Evidence

Key studies supporting cGAS-STING involvement in PD:

cGAS-ST

The cGAS-STING pathway activates NF-κB through TRAF6 recruitment, creating a complex network of pro-inflammatory s- cGAMP-STING activates TAK1

• TAK1 phosphorylates IKK complex
• IKK phosphorylates IκB, releasing NF-κB
• NF-κB translocates to nucleus, inducing inflammatory genes

Interactions with Other Neurodegenerative Pathways

• p53 Pathway: cGAS-STING activates p53, potentially enhancing neuronal apoptosis
• autophagy: STING degradation is autophagy-dependent; impaired autophagy increases STING signaling
• NLRP3 Inflammasome: cGAS-STING synergizes with NLRP3 for maximal cytokine production

Summary

The cGAS-STING pathway provides a molecular link between DNA damage, mitochondrial dysfunction, and neuroinflammation in Parkinson's disease. Chronic activation of this pathway contributes to progressive dopaminergic neuron loss through interferon-dependent and independent mechanisms. Targeting cGAS-STING represents a promising therapeutic strategy to interrupt the neuroinflammatory cascade in PD.

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)